MabVax Therapeutics Holdings Inc. said it received a delisting determination from Nasdaq Stock Market LLC.
MabVax directors previously decided against planning to regain compliance with the exchange's listing rules.
MabVax was not in compliance with the exchange's listing requirements for stockholders' equity and periodic report filings. MabVax underwent a Securities and Exchange Commission investigation regarding its financial and registration statements.
The San Diego-based biopharmaceutical company will not appeal the decision, and its common stock will be suspended from the Nasdaq Capital Market on July 11.